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An important study by van der Horst et al. (1) from the
Netherlands reported in this issue of the Journal presents the
results of the largest prospectively randomized trial of
glucose-insulin-potassium (GIK) treatment for acute myo-
cardial infarction (AMI) ever done (940 patients) and the
first to be done in concert with rapid, successful percutane-
ous transluminal coronary angioplasty (PTCA). The most
important result was that GIK increased survival impres-
sively in the 91% of patients who presented without heart
failure (HF) (Killip class 1), reducing the 30-day mortality
risk from 4.2% in the control group to 1.2% in the GIK
group (p  0.01, relative risk reduction of 72%). In
diabetics, there was a non-significant trend toward reduced
mortality with GIK.
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However, GIK was not beneficial in patients who pre-
sented with HF, possibly because the GIK was infused at a
relatively high rate, twice as high as the Estudios Cardio-
logicos Latinoamerica (ECLA) study (2), and caused a
volume overload. In the 4% of patients who presented with
mild HF (Killip class 2), GIK treatment was neither
beneficial nor harmful. In the 5% who presented with severe
HF (Killip classes 3 and 4), the mortality risk was higher in
the GIK group than in the control group. But the small
sample sizes preclude reaching statistically significant, def-
inite conclusions about the effects of GIK in AMI patients
with HF.
The results in the patients with HF are a dilemma of
interpretation. Despite the small sample size and lack of
statistical significance, because of their potential clinical
importance, the non-significant trends cannot be completely
ignored. Some insight may be gained by comparing the
infusion rates and results of the current Dutch study with
other large, randomized trials of GIK in AMI patients with
HF.
The ECLA experience. In 1998, the ECLA group ran-
domized 407 AMI patients, 62% of whom received reper-
fusion therapy, to GIK or control treatment. There was a
remarkable 66% reduction in the relative in-hospital mor-
tality risk when GIK was added to reperfusion (2,3). The
absolute mortality risk decreased from 15.2% in the control
group to 5.2% in the GIK group.
A comparison of the Dutch and ECLA studies reveals
areas of agreement and disagreement. In both trials, more
than 85% of the AMI patients presented without signs of
congestive heart failure (CHF). Glucose-insulin-potassium
in combination with reperfusion (which was done by
thrombolysis in 95% of cases in the ECLA study and solely
by PTCA in the Dutch study) was highly beneficial in such
non-CHF cases; the relative reductions in mortality risk
conferred by GIK were 72% and 66% in the Dutch and
ECLA studies, respectively.
However, the ECLA results in patients who presented
with HF are in the opposite direction to those of the present
Dutch study. In the ECLA study there was a non-
significant trend towards a lower mortality risk in the HF
and shock patients who received GIK. An important treat-
ment difference, and a possible explanation of the different
results between these two studies, was the intravenous rate
of volume loading, which was twice as high in the Dutch
study as in the ECLA study (3 vs. 1.5 ml/kg/h). Thus, in
the Dutch study, an 80-kg patient with CHF received
approximately 2 l of fluid in the first 8 h.
The potential of GIK to influence mortality risk in the
Killip class 3 and 4 cases in the Dutch study was also limited
by the relatively low rate of successful reperfusion in these
cases. Only 50% of the Killip class 3 and 4 cases had
successful reperfusion; the ECLA results suggest the GIK is
beneficial only in concert with reperfusion (2). In the entire
Dutch study of 940 patients, only 23 Killip class 3 and 4
patients had successful reperfusion; such a small sample
precludes any definite conclusions.
Texas Heart Institute experience. Also discrepant with
the Dutch study are results from Taegtmeyer et al. (4) in
322 consecutive patients with refractory HF immediately
after cardiac surgery who were randomly treated with
“standard care” or “standard care  GIK.” The addition of
GIK to the standard regimen of inotropic drugs and
intra-aortic balloon counterpulsation reduced in-hospital
mortality by 34% (from 26.6% to 17.6%, p  0.02); the
infusion rates were 0.5 to 1.0 ml/kg/h, maximally only
one-third of the rate used in the Dutch study.
In an experimental model of cardiogenic shock induced
by multiple coronary occlusions, GIK substantially increased
short-term survival (5), consistent with the Taegtmeyer
results.
Considered together, these studies suggest that GIK may
be potentially beneficial in AMI and post-cardiac surgery
patients with HF and/or shock, but that GIK’s metabolic
benefit can be outweighed by excessive volume loading. In
the presence of HF or shock, a reasonable strategy might
employ a more concentrated GIK solution with a lower
infusion rate as was done in the ECLA and Texas Heart
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Institute studies. Placement of a central line and careful
hemodynamic monitoring would be advisable in such cases.
Timing and duration of GIK relative to the onset and
duration of ischemia. The different time frames of GIK
treatment in the ECLA and Dutch studies raise some
interesting clinical issues. In the former study, the time from
onset of symptoms to hospital admission was 10 to 11 h;
this was only 2.5 h in the latter study. Thus, in these two
studies, GIK reduced AMI mortality risk similarly in
non-CHF cases, despite a wide range of duration of
ischemia before treatment. Furthermore, in both studies
GIK had an impressive protective effect despite its being “on
board” for a relatively small fraction of the ischemic pre-
reperfusion period. For example, in the ECLA study,
ischemia had been present for 10 to 11 h before hospital
admission; assuming that thrombolysis was given promptly,
and resulted in reperfusion within 2 h of arrival at hospital,
GIK was infused for only approximately 15% (2 of 13 h) of
the pre-reperfusion ischemic time. Similarly, in the Dutch
study, ischemia had been present for 2.5 h before admission,
and the admission-to-PTCA time was approximately 45
min. Assuming GIK was infused for 30 of those 45 min, the
GIK would have been given for only 15% (30 of 195 min)
of the ischemic pre-reperfusion period.
The fact that GIK was effective, despite being present for
only a relatively brief period before reperfusion, suggests
several possibilities. The GIK may protect against “reper-
fusion injury” or provide important metabolic support dur-
ing reperfusion (6), and/or the GIK may be able to reverse
some of the ischemic injury that has occurred before its
being administered. Also, there is clearly a potential for
increasing the benefits of GIK by its earlier administration
(e.g., when the patient is first seen by ambulance personnel);
this could increase the fraction of ischemic pre-reperfusion
time during which GIK could provide metabolic protection.
These issues require further research.
Mechanisms of mortality reduction by GIK. In the
current Dutch study, GIK appeared to decrease mortality by
preventing the development of HF; 91% of the study
population presented without HF (Killip class 1); the
subsequent development of HF was responsible for 67% of
the deaths in the Killip class 1 patients who did not receive
GIK. Glucose-insulin-potassium treatment may prevent
HF by reducing infarct size (cell death from both ischemia
and reperfusion injury) and by providing an additional
energy substrate that supports the non-infarcted myocardi-
um’s ability to cope with a sudden mechanical load.
GIK’s metabolic actions against ischemic-reperfusion
injury and necrosis. During an AMI, plasma free fatty acid
(FFA) levels rapidly increase because of the lipolytic effects
of catecholamines and/or heparin. The increased FFA levels
are toxic to ischemic myocardium and are associated with
increased membrane damage, arrhythmias, metabolic inef-
ficiency, and decreased cardiac function. Glucose-insulin-
potassium decreases FFA toxicity by decreasing circulating
FFA levels and myocardial FFA uptake and oxidation
(7–9).
Shifting myocardial oxidative metabolism from FFA to
glucose oxidation makes the myocardium more “oxygen
efficient”; approximately 11% more adenosine triphosphate
(ATP) is synthesized per mole of oxygen when glucose is
oxidized rather than FFA, and left ventricular (LV) function
relative to oxygen consumption is improved when glucose,
rather than FFA, is the major oxidative substrate (10,11).
Despite a coronary occlusion, substantial oxidative ATP
synthesis occurs in an acute infarct region because a signif-
icant degree of residual perfusion is almost always present
(12); thus GIK has the potential to improve oxidative
metabolic efficiency in the ischemic and infarcting regions.
The effect of GIK to increase glycolytic ATP synthesis is
also important. During low-flow ischemia, with perfusion
levels comparable to those in the infarct region in patients
with AMI, provision of high glucose and insulin caused a
small but significant increase in ischemic glycolytic ATP
production, with consequent attenuation of both the
ischemia-induced decreases in ATP and phosphocreatine
and the reciprocal increases in inorganic phosphate (Pi) and
adenosine diphosphate (ADP) levels (13–15). The resulting
combination of a higher [ATP] and lower [Pi] and [ADP]
resulted in a higher calculated free energy yield from ATP
hydrolysis for all cellular adenosine triphosphatase reactions.
The intracellular location of glycolytic enzymes may
provide glycolytic ATP with particular value in the main-
tenance of critical membrane functions such as calcium and
sodium homeostasis (16–20). A high glucose substrate level
also increases myocyte resistance to the toxic effects of the
increase in cell calcium levels that occurs during hypoxia
(21).
Insulin alone exerts beneficial metabolic and functional
effects during ischemia (22,23). Also, insulin given during
early reperfusion reduced infarct size, possibly by reducing
reperfusion apoptosis (24). The net effect of these GIK
actions is the reduction of cellular injury from ischemia and
reperfusion, and improved ischemic and post-ischemic sys-
tolic and diastolic function (13).
Metabolic support for the acutely loaded non-infarct
region. An AMI acutely mechanically overloads the non-
infarct region of the ventricle in proportion to myocardial
infarct (MI) size, and the functional response of the non-
infarct region may determine whether HF occurs. Recent
elegant work from Liao et al. (25) has shown that normal
myocardium is metabolically limited in its ability to adapt to
an acute mechanical overload. After aortic banding, wild-
type mice had a decreased high-energy phosphate profile,
developed rapid LV failure, and had a mortality rate of 40%
at eight weeks. In contrast, transgenic mice with a cardiac-
specific overexpression of the glucose transporter, GLUT 1,
had a markedly increased level of glucose uptake, main-
tained a normal high-energy phosphate profile, normal LV
function, and had a very low mortality rate. Thus, enhanced
cellular glucose uptake appears to be essential to the func-
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tion and survival of acutely overloaded myocardium. By
increasing glucose availability and uptake, GIK may provide
important metabolic support to the acutely overloaded
non-infarct region.
Renewed interest in myocardial metabolism, lessons
learned, and future questions. The current Dutch study
contributes importantly to the clinical revival of metabolic
support for the ischemic myocardium that began in the
1970s with the pioneering studies from the Rackley group
(26), a meta-analysis of GIK treatment of AMI (27,28), and
the Diabetes Mellitus, Insulin-Glucose Infusion in Acute
Myocardial Infarction (DIGAMI) study (29,30). The meta-
analysis reviewed all previous randomized trials of GIK for
AMI (these were all done in the pre-thrombolytic era). The
majority of such trials were very poorly designed, often
giving small amounts of GIK or starting therapy too late to
be useful. In the nine randomized trials involving 1,932
patients, where GIK was given intravenously and started at
an adequate dosage within 48 h of symptoms, GIK reduced
relative in-hospital AMI mortality by 28%; furthermore, in
the four studies in which GIK was administered at high
concentrations to maximally suppress plasma FFA levels,
relative AMI mortality risk was reduced by 48%. The
Swedish DIGAMI study tested an insulin-glucose infusion,
followed by multidose insulin treatment, in diabetics with
AMI. The insulin-glucose treatment resulted in relative
mortality decreases of 29% and 25% at one and three years
of follow-up, respectively. These results, and those from the
subsequent ECLA study and the current Dutch study, all
support the principle that cardiac energy metabolism is an
area deserving further research for the treatment of myo-
cardial ischemia.
However, the results from the Dutch and ECLA studies
should not be considered conclusive; before GIK is added to
the therapeutic canon, larger trials are needed. Both trials
were relatively small, and in each study a statistically
significant reduction in mortality occurred only in a sub-
group, not in the total population studied. In the ECLA
study, GIK reduced AMI mortality significantly in the
subgroup that received concomitant reperfusion treatment.
In the Dutch study, the statistically significant mortality
reduction occurred in the non-CHF subgroup. Even though
these subgroups were prospectively defined and represented
the majority of patients in each study, a conclusion based on
a subgroup result is not as convincing as a result from the
entire study population.
Whether GIK is beneficial in all patients with AMI is a
crucial issue to resolve. Approximately 1.1 million MIs
occur each year in the U.S. The Dutch results suggest that
approximately one million present initially without CHF
and that GIK has the potential to reduce their absolute
mortality risk by 3%, saving the lives of approximately
30,000 such patients each year.
Whether GIK is beneficial in AMI patients with CHF
and/or shock is an equally crucial issue to resolve. Although
such patients comprise a relatively small percentage of the
total AMI population, they have the highest mortality risk,
but are also the least tolerant of a large volume infusion.
Extrapolation from the Dutch study suggests that approxi-
mately 99,000 AMIs of Killip class 2 or higher occur
annually in the U.S., with a mortality risk of 26.5%,
resulting in 26,235 deaths per year despite rapidly available
PTCA. A trial of a relatively concentrated GIK solution
with low infusion rates, such as was used by Taegtmeyer et
al. (4), would seem appropriate in such cases. Because
patients with CHF and shock comprise a relatively small
percentage of the total AMI population, a multicenter trial
is probably required to resolve this issue.
Is GIK treatment for AMI beneficial in the general
community outside of specialized centers? Would its bene-
fits be increased by starting treatment as early as possible
after the onset of symptoms and giving it during transport to
a hospital site of revascularization? All these issues need to
be resolved. The stakes are high; although such research is
costly, treatment with GIK is cheap and the potential
benefits are large.
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